HealthCare Institute of New Jersey
09/01/2026 | Press release | Archived content
In the News: HINJ Quoted in NJBIZ on Drug Pricing Policy
September 1, 2026 ― HealthCare Institute of New Jersey (HINJ) was featured in a recent NJBIZ article examining the White House's newly announced voluntary prescription drug pricing agreements and their implications for New Jersey's life sciences industry.
In comments included in the article, HINJ President & CEO Chrissy Buteas highlighted the importance of pursuing patient affordability solutions that do not undermine medical innovation.
"Today's voluntary agreements show that there are ways to reduce costs for patients without jeopardizing the research, discovery, and development of tomorrow's life-saving treatments and cures."
Buteas noted that voluntary agreements recognize the significant investments biopharmaceutical companies make in research and development and allow stakeholders to work collaboratively toward lowering costs while preserving America's innovation leadership. She reaffirmed HINJ's commitment to working with policymakers to advance sustainable solutions that support both patients and the development of future treatments and cures.
Read the full article: NJ Pharma Reacts to White House Drug Price Deals
HealthCare Institute of New Jersey published this content on September 01, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 11, 2026 at 18:54 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]